Assessment of Post-COVID-19 Complications and Vaccination Efficacy

Dear Colleagues,

COVID-19 vaccination has been found to reduce the risk of SARS-CoV-2 transmission as well as hospitalization and associated complications. This is in part attributed to vaccine efficacy in its ability to induce both humoral and cell-mediated immune responses in vaccinated subjects. There are different types of vaccines being used worldwide, including inactivated virus, adenovirus vector vaccines, mRNA vaccines, etc. In India, we have not yet started vaccinating subjects under 18 yrs of age. Clinical trials are underway for subjects under 18 years. Currently, vaccination is approved for 18-44 years and above age group. There is a need to study vaccine efficacy and its ability to protect against SARS-CoV-2 infection, including reducing the virus spread, inducing sustainable immunity, and reducing hospitalization and progression to COVID-19 complications in subjects across different age groups and in those having comorbidities. In this Special Issue, we call for articles that address post-COVID-19 vaccination efficacy and complications. Original articles, short communications, review articles, and commentaries are also welcome.

Dr. P Veeranna Ravindra
Prof. Dr. Prashant Chikkahonnaiah
Dr. Federico Pratesi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.